the developed world. In the United States, heart failure is projected to result in over $70B in treatment costs annually.

MyCardia is a stable and robust allogeneic engineered tissue graft that can be manufactured at scale, cryopreserved, and shipped at room temperature.  In pre-clinical studies of heart failure, MyCardia resulted in improved left ventricular volume (systole and diastole) and myocardial mass, in addition to improved quality of life metrics such as daily activity and exercise tolerance, compared to untreated cohorts.